VSTM – Verastem, Inc.
Verastem, Inc.VSTM
$5.33Name : Verastem, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $237,219,648.00
EPSttm : -3.14
Verastem, Inc.
$5.33
0.95%$0.05Float Short %
7.8
Margin Of Safety %
Put/Call OI Ratio
0.16
EPS Next Q Diff
-0.21
EPS Last/This Y
0.98
EPS This/Next Y
0.61
Price
5.31
Target Price
12.29
Analyst Recom
1
Performance Q
60.06
Relative Volume
0.45
Beta
0.26
Ticker: VSTM
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | VSTM | 4.45 | 0.15 | 0.00 | 6852 |
| 2024-12-20 | VSTM | 4.2 | 0.15 | 0.13 | 6860 |
| 2024-12-23 | VSTM | 3.97 | 0.07 | 0.05 | 2826 |
| 2024-12-24 | VSTM | 3.9 | 0.07 | 0.00 | 2982 |
| 2024-12-26 | VSTM | 3.95 | 0.07 | 0.10 | 3175 |
| 2024-12-27 | VSTM | 3.71 | 0.07 | 0.01 | 3302 |
| 2024-12-30 | VSTM | 3.68 | 0.07 | 0.04 | 3490 |
| 2024-12-31 | VSTM | 5.17 | 0.07 | 0.18 | 3601 |
| 2025-01-02 | VSTM | 6.51 | 0.12 | 0.16 | 5505 |
| 2025-01-03 | VSTM | 6.99 | 0.19 | 0.08 | 6430 |
| 2025-01-06 | VSTM | 6.72 | 0.19 | 0.03 | 6944 |
| 2025-01-07 | VSTM | 6.55 | 0.19 | 0.15 | 7085 |
| 2025-01-08 | VSTM | 5.9 | 0.20 | 0.01 | 7030 |
| 2025-01-09 | VSTM | 5.9 | 0.20 | 0.02 | 7030 |
| 2025-01-10 | VSTM | 5.72 | 0.19 | 0.40 | 7152 |
| 2025-01-13 | VSTM | 5.35 | 0.19 | 2.93 | 7189 |
| 2025-01-14 | VSTM | 5.06 | 0.16 | 0.38 | 7057 |
| 2025-01-15 | VSTM | 5.32 | 0.16 | 0.07 | 7061 |
| 2025-01-16 | VSTM | 5.29 | 0.16 | 0.03 | 7069 |
| 2025-01-17 | VSTM | 5.33 | 0.16 | 0.03 | 7067 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | VSTM | 4.45 | 33.0 | - | -2.98 |
| 2024-12-20 | VSTM | 4.20 | 33.0 | - | -2.98 |
| 2024-12-23 | VSTM | 3.96 | 33.0 | - | -2.98 |
| 2024-12-24 | VSTM | 3.90 | 33.0 | - | -2.98 |
| 2024-12-26 | VSTM | 3.94 | 33.0 | - | -2.98 |
| 2024-12-27 | VSTM | 3.72 | 33.0 | - | -2.98 |
| 2024-12-30 | VSTM | 3.68 | 33.0 | - | -2.98 |
| 2024-12-31 | VSTM | 5.17 | 33.0 | - | -2.98 |
| 2025-01-02 | VSTM | 6.51 | 33.0 | - | -2.98 |
| 2025-01-03 | VSTM | 6.98 | 33.0 | - | -2.98 |
| 2025-01-06 | VSTM | 6.73 | 33.0 | - | -2.98 |
| 2025-01-07 | VSTM | 6.57 | 33.0 | - | -2.98 |
| 2025-01-08 | VSTM | 5.90 | 33.0 | - | -2.98 |
| 2025-01-09 | VSTM | 5.90 | 33.0 | - | -2.98 |
| 2025-01-10 | VSTM | 5.73 | 33.0 | - | -2.98 |
| 2025-01-13 | VSTM | 5.35 | 33.0 | - | -2.98 |
| 2025-01-14 | VSTM | 5.05 | 33.0 | - | -2.98 |
| 2025-01-15 | VSTM | 5.31 | 33.0 | - | -2.98 |
| 2025-01-16 | VSTM | 5.28 | 33.0 | - | -2.98 |
| 2025-01-17 | VSTM | 5.31 | 33.0 | - | -2.98 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | VSTM | -0.16 | 187.17 | 5.06 |
| 2024-12-20 | VSTM | -0.16 | 187.17 | 5.06 |
| 2024-12-23 | VSTM | -0.17 | 187.16 | 5.06 |
| 2024-12-24 | VSTM | -0.17 | 187.16 | 5.06 |
| 2024-12-26 | VSTM | -0.16 | 187.16 | 6.61 |
| 2024-12-27 | VSTM | -0.16 | 187.16 | 6.61 |
| 2024-12-30 | VSTM | -0.17 | 187.16 | 6.61 |
| 2024-12-31 | VSTM | -0.17 | 187.16 | 6.61 |
| 2025-01-02 | VSTM | -0.11 | 187.16 | 6.61 |
| 2025-01-03 | VSTM | -0.16 | 187.16 | 6.61 |
| 2025-01-06 | VSTM | -0.15 | 187.16 | 6.61 |
| 2025-01-07 | VSTM | -0.15 | 187.16 | 6.61 |
| 2025-01-08 | VSTM | -0.16 | 187.16 | 6.61 |
| 2025-01-09 | VSTM | -0.16 | 187.16 | 6.61 |
| 2025-01-10 | VSTM | -0.16 | 187.16 | 6.61 |
| 2025-01-13 | VSTM | -0.16 | 187.16 | 7.80 |
| 2025-01-14 | VSTM | -0.16 | 187.16 | 7.80 |
| 2025-01-15 | VSTM | -0.34 | 187.16 | 7.80 |
| 2025-01-16 | VSTM | -0.34 | 187.16 | 7.80 |
| 2025-01-17 | VSTM | -0.34 | 187.16 | 7.80 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.6
Avg. EPS Est. Current Quarter
-0.74
Avg. EPS Est. Next Quarter
-0.81
Insider Transactions
-0.34
Institutional Transactions
187.16
Beta
0.26
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
15
Growth Score
37
Sentiment Score
6
Actual DrawDown %
91
Max Drawdown 5-Year %
-96.2
Target Price
12.29
P/E
Forward P/E
PEG
P/S
23.72
P/B
19.4
P/Free Cash Flow
EPS
-3.19
Average EPS Est. Cur. Y
-2.98
EPS Next Y. (Est.)
-2.37
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-934.54
Relative Volume
0.45
Return on Equity vs Sector %
-309.1
Return on Equity vs Industry %
-296.5
EPS 1 7Days Diff
0.7
EPS 1 30Days Diff
0.37
EBIT Estimation
Verastem, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 73
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
stock quote shares VSTM – Verastem, Inc. Stock Price stock today
news today VSTM – Verastem, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VSTM – Verastem, Inc. yahoo finance google finance
stock history VSTM – Verastem, Inc. invest stock market
stock prices VSTM premarket after hours
ticker VSTM fair value insiders trading